All tumors were examined by routine hematoxylin and eosin (H & E) staining and a panel of monoclonal antibodies (MAbs) using immunoperoxidase techniques (Table 1) . Where appropriate, the microwave heat enhancement technique was used. 43, 51 For a complex variety of reasons, tests using the complete panel of MAbs could not be performed on all specimens. Seventeen tumors were studied for ultrastructural features with standard techniques, and 11 children were examined postmortem.
Chromosomal studies were performed on 12 cases from our institution and five tumors were sent for consultation. Karyotypes were prepared according to established methods. 3 The cytogenetic findings from six of the cases have been reported previously. 3, 4, 20 Interphase fluorescence in situ hybridization (FISH) was performed as described 5 with a chromosome 22-specific cosmid probe for 22q11.2 and a probe from the Ewing's sarcoma region in 22q12.
Results

Clinical Features
The ATT/RhT is clearly a tumor of infancy and childhood, with a mean age at diagnosis of 29 months and a median of 16.5 months. Except for one infant who was diagnosed in utero, the ages ranged from 22 days to 14.9 years. Three-quarters of the patients were aged 3 years or younger at the time of diagnosis. There was a 3:2 male predominance. The site of origin, clinical symptoms, and extent of tumor are listed in Table 2 .
Tumors were infratentorial in 33 patients (63%), supratentorial in 14 (27%), in multiple sites in four (8%), and in the extramedullary cervical spinal cord in one infant. Twenty-eight (70%) of the 40 children younger than 3 years of age at diagnosis had a posterior fossa tumor, in contrast to only four (33%) of 12 older children. Eight of 10 hemispheric masses were left sided. Two of the four patients with tumors in multiple sites at diagnosis were older than 3 years of age at the time.
Clinical presentation was consistent with the location of the tumors at the time of diagnosis. Eighteen children younger than 3 years of age presented with nonspecific signs such as lethargy, vomiting, and/or failure to thrive. Six children with posterior fossa tumors developed head tilts before any other symptoms were obvious. Of the 18 children with cranial nerve problems, 13 had sixth nerve paresis, and seven had facial weakness. Only one child in the series presented with lower cranial nerve deficits. Headaches occurred primarily in children (seven of eight) older than 3 years of age. Hemiplegia was also more common in older patients.
Forty-one of the 52 patients underwent an adequate evaluation for disseminated disease at the time of diagnosis (myelography or gadolinium-enhanced spinal magnetic resonance (MR) imaging, and cerebrospinal fluid cytological examination). Of these, 14 (34%) had leptomeningeal dissemination. There was no difference in age at diagnosis in those who had disseminated disease and those who did not.
Radiological Features
The radiological features of this tumor are similar to routine PNET-MB. There is increased density on unenhanced computerized tomography images and inhomogeneous contrast enhancement. Cysts and hemorrhages are common. With MR imaging there is decreased density on T 1 -weighted images, iso-or decreased density on T 2 -weighted images, isointensity on proton density, and enhancement with gadolinium ( Fig. 1) .
Treatment Protocols
Treatment was individualized because patients were collected from many different centers (Table 3) . A biopsy specimen of the tumor was taken in five children and in 31 J. Neurosurg. / Volume 85 / July, 1996 Atypical teratoid/rhabdoid tumors in infancy and childhood * AE1/AE3 = low-and high-molecular-weight cytokeratin; EMA = epithelial membrane antigen; GFAP = glial fibrillary acidic protein; HCG = human chorionic gonadotropin; Ker = cytokeratin; MH = microwave heating; NFP = neurofilament protein; PAP = placental alkaline phosphatase; SMA = ␣-smooth-muscle actin. the tumor was partially resected. Total or near-total resection, as assessed by the neurosurgeon and the postoperative imaging studies, was achieved in 16 patients. Nine children did not receive any treatment after surgery and died within 1 month. Thirty-nine patients received chemotherapy at the time of diagnosis and an additional eight after tumor progression following initial chemotherapy or radiotherapy. Different chemotherapeutic agents and regimens were used including the "baby POG" protocol (cyclophosphamide, vincristine, cisplatinum, and VP-16) in seven, an augmented baby POG regimen with higher dose cyclophosphamide and more intensive cisplatinum in nine, eight-drugs-in-one-day therapy in seven, and other multiple-agent cisplatinum-or carboplatinum-based regimens in six. Single-agent cyclophosphamide was used in one patient and single ifosphamide in another. Two children were treated with high-dose thiotepa, carboplatinum, and 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea followed by autologous bone marrow transplantation at diagnosis, and another with a mephalan-based transplantation regimen after initial response to chemotherapy. None of the eight children who were treated using a total of 10 different chemotherapeutic regimens at the time of relapse after initial radiotherapy or chemotherapy had an objective response to treatment. Of the 33 children who received chemotherapy alone after surgery and the three who received chemotherapy prior to radiotherapy, six had a documented greater than 50% reduction in tumor mass, including two who had received the augmented baby POG regimen, one the eight-drug-in-one-day therapy, two an alternative cisplatinum regimen, and one who had received high-dose cyclophosphamide and VP-16. The longest lasting response to chemotherapy was 10 months. Thirteen children received radiotherapy at some point during their treatment course. The radiotherapy was given at the time of diagnosis in 10 children (six with either preor postradiotherapy chemotherapy) and at the time of relapse in three. Objective responses to radiotherapy were demonstrable in two of the 10 patients with disease that could be evaluated.
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Patient Outcome
At the time of this analysis, 43 of the 52 children had died from progressive disease. One child died of sepsis while receiving chemotherapy. The median time to progression was 4.5 months and the median time of overall survival was 6 months. There was no clear difference in survival or progression-free survival as a function of age. The median time to progression was 6 months in the 21 patients who were younger than 3 years of age at diagnosis and who received some form of treatment postsurgically, as compared to 7.5 months in older patients. Six children did not receive any form of adjuvant treatment following surgery (two were older than 3 years). The longest-surviving patient, a 3-year-old girl with a thalamic tumor, lived for 5 1/2 years after receiving craniospinal radiotherapy, but then developed fatal local and metastatic disease recurrence. Eight patients in this series are alive at 2 to 12 months after diagnosis (median 6 months). Initial treatment failed in four of the children still alive, and they are now receiving alternative therapy for progressive disease. Two of the eight children were younger than 2 years of age and four were older than 3 years of age at diagno- sis. Four children had received craniospinal radiotherapy (two with adjuvant chemotherapy). Two of the three children treated with high-dose chemotherapy and bone marrow transplantation have died; the other is in stable condition 2 months after receiving treatment. Patterns of first relapse included local alone in 14 children, leptomeningeal dissemination alone in five, and local and leptomeningeal dissemination in 26. Ten of the children who developed disseminated disease at the time of first relapse had negative staging studies. Two of the children with local disease relapse ultimately developed leptomeningeal spread.
Routine Light Microscopic Features
All tumors contained nests or sheets of rhabdoid cells; in fact, seven (13%) of the 52 tumors consisted solely of such cells (Fig. 2 upper left) . Thirty-five (67%) of 52 tumors had fields that resembled classic PNETs (Fig. 2 upper right) and 16 (31%) of 52 contained a malignant mesenchymal component (Fig. 2 lower left) . Least common was evidence of epithelial differentiation, in 13 (25%) of 52 ( Fig. 2 lower right, Table 4 ).
The typical rhabdoid cell has an eccentric round nucleus with a prominent nucleolus and a plump cell body ( Fig.  2 upper left) . This may be homogeneous or may contain a denser round indistinct "inclusion." Morphological features of these rhabdoid cells, however, are variable; some may be small and spindle shaped with an ovoid nucleus, whereas others are quite large and have a nucleus with a wrinkled border and two nucleoli. These large nuclei often have an empty appearance. Mitotic figures are typically abundant and field necrosis is also common.
The rhabdoid component in those tumors with mixed histological elements tends to be distinctly separate from the other elements. However, a nest of rhabdoid cells may be adjacent to or surrounded by otherwise typical PNET (or vice versa, Fig. 3 left) , or a nest of epithelial cells or PNET may occupy the same relationship to the mesenchymal component (Fig. 3 right) . The mesenchymal and/ or epithelial components may occur within the rhabdoid fields with no evidence of PNET features.
The PNET fields for the most part are made up of typical small cells with deeply basophilic round-to-oval nuclei surrounded by little discernible cytoplasm. Rarely, Flexner-Wintersteiner or Homer Wright rosettes are found, but nodules and linear cellular arrays typical of socalled "desmoplastic medulloblastoma" have not been observed in this material. Tubular structures resembling primitive neural tubes are rarely present.
The mesenchymal areas are typically composed of loosely arrayed spindle-shaped cells separated by pale "ground substance." One tumor, however, was predominantly mesenchymal and was characterized by a dense growth of tumor cells resembling a fibrosarcoma, with the rhabdoid, PNET, and epithelial fields much less conspicuous. 30 One focus of chondroidlike tissue was found in one tumor.
Epithelial differentiation is the least common histological feature and in the majority of tumors exhibited an adenomatous or papillary pattern. In fact, two of these tumors were initially diagnosed as choroid plexus carcinoma. In only one tumor was the epithelium of squamous type, and in one additional unique lesion the epithelium took the 
Immunohistochemical Studies
Patterns of positivity noted on application of a panel of MAbs are complex. Early studies of these tumors included a large number of different antibodies, but it was found from experience that seven are most helpful in distinguishing this group of tumors from other primary CNS neoplasms, most specifically germ-cell tumors and classic PNETS (Table 5) .
There are three antibodies whose epitopes are almost always expressed: epithelial membrane antigen (EMA), vimentin, and smooth-muscle actin. The extent of expression varies from minimal to abundant, but the majority of tumors display strong positivity for one or more antibodies. Markers for germ-cell tumors, including ␣-fetoprotein, placental alkaline phosphatase, and human chorionic gonadotropin, are always negative.
Certain patterns of staining are characteristic: 1) EMA is primarily expressed in the rhabdoid cells, less consistently in the epithelial cells, and never in the mesenchymal or PNET portions. Only the cell membrane or, alternatively, the entire perikaryon, may be stained (Fig. 4 left) .
2) Vimentin expression is striking in the cytoplasm of the rhabdoid cells, blood vessels, and in the mesenchymal areas, but is inconsistently or only minimally positive in the epithelial and PNET fields (Fig. 4 right) . 3) Smoothmuscle actin positivity is basically localized to the rhabdoid cells and the blood vessels, although mesenchymal tissue is occasionally stained (Fig. 5 left) . 4) The two primary neural antibodies, glial fibrillary acid protein (GFAP) and neurofilament protein (NFP), may be positive in both the PNET fields and the rhabdoid cells, in the latter often strikingly so (Figs. 5 right and 6 left). 5) Keratin is basically confined to the epithelial tissue and the rhabdoid cells (Fig. 6 right) . 6) Desmin expression is exceptionally sparse even when present and is typically confined to the mesenchymal and PNET fields.
Ultrastructural Features
Ultrastructural features are variable and related to sampling. Whorled bundles of intermediate filaments filling some or most of the perikaryon are identified in those tumors in which the rhabdoid cells are included in the specimen (Fig. 7) . Typical features that have been described for PNETs, adenomatous and squamous epithelial cells, and poorly-differentiated mesenchymal tumors could be found in the samples.
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Cytogenetic Studies
Cytogenetic or FISH studies could be evaluated for 15 of 17 cases received for study. Seemingly normal karyotypes were obtained from five samples. The FISH studies were performed on two of the tumors with normal karyotypes, neither of which had a submicroscopic deletion of chromosome 22. Abnormalities of chromosome 22 were detected in nine of 15 cases. Five had monosomy 22 and four had partial deletions of chromosome 22. In each of these four, the deletion resulted from a break in the proximal region of chromosome 22q11. One of the 15 cases had a karyotype with loss of chromosomes 6 and 13, deletion of the distal short arm of chromosome 17, and two markers, but normal chromosome 22. There is an insufficient number of cases to make clinicopathological comparisons between the patients with chromosome 22 abnormalities and those whose chromosomal studies yielded no deviations.
Autopsy Findings
Eleven patients were examined postmortem. The tumor had spread widely throughout the subarachnoid space in all but one instance. The histological features were essentially similar to those observed at biopsy in all cases except for one infant whose tumor posttreatment consisted solely of rhabdoid cells, whereas the primary lesion contained a mixture of all major histological patterns, including rhabdoid, PNET, mesenchymal, and epithelial. A second infant presented another interesting variation; some tumor masses consisted solely of PNET or rhabdoid tumor.
Discussion
We have studied 52 infants and children with biologically malignant primary CNS tumors, some or all of which consist of rhabdoid cells similar to those that form a rapidly fatal infantile tumor of the kidney. The monomorphic CNS tumors have not been difficult to recognize and have been reported as primary CNS rhabdoid tumor. 1, 6, 8, 10, 11, 21, 22, 24, 25, 29, 32, 36, 44, 47, 49, 50 On the contrary, a larger group composed of a mixture of rhabdoid cells, fields indistinguishable from classic PNETs, with or without additional features of mesenchymal and/or epithelial tissue, have been categorized most commonly as PNET-MB. Such confusion may account for the perception that infants with PNET-MB who are 2 years old or younger have a worse prognosis than do other children with such tumors. It is, therefore, crucial that clinicians and pathologists alike familiarize themselves with the clinical, pathological, and biological characteristics of the ATT/RhTs, which are almost uniformly fatal within 1 year of diagnosis. This type of tumor has not, to date, been found in adults.
The clinical characteristics of the 52 patients whom we studied are somewhat different from those of children with classic PNETs. Childhood PNETs, including medulloblastoma, tend to appear between 3 and 5 years of age, whereas ATT/RhTs, are more likely to be diagnosed at an earlier age, the median age at diagnosis being 16.5 months. As in other series of children with PNET-MB, there is a male predominance. Children with cerebral ATT/RhT are more likely to present at a somewhat older age. The patients in this series had symptoms consistent with a tumor location within the neuraxis. A sizable minority of children younger than 2 years of age presented with nonspecific symptoms such as failure to thrive and unexplained lethargy.
The majority of patients with ATT/RhT succumb within 1 year of diagnosis, in contrast to children with PNET-MB, among whom there is at least a transient response to chemotherapy in 40% to 60%. Children with ATT/RhTs rarely respond to treatment despite the use of aggressive chemo-and/or radiotherapy. Overall survival is poor and unrelated to the age of the patient at the time of diagnosis, extent of resection, or the type of adjuvant postsurgical therapy. The longest survival period was 5 1/2 years in a 3-year-old child who already had subarachnoid spread of the tumor at initial diagnosis.
One-third of patients with ATT/RhTs had evidence of leptomeningeal dissemination at the time of diagnosis.
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Atypical teratoid/rhabdoid tumors in infancy and childhood This is not different from the rates of dissemination reported for children with PNETs. Atypical teratoid tumors are also frequently disseminated in the neuraxis at the time of disease relapse, including in those patients with apparent localized disease at the time of diagnosis.
In contrast to classic PNETs, which arise in the cerebellum 80% of the time, the ATT/RhT develops in that site in only slightly over half of the children. The cerebellopontine angle appears to be a common location for ATT/RhTs; eight (15%) of 52 tumors were found only in that region or occurred both there and in another site on presentation.
Separation of ATT/RhTs from classic PNETs is difficult on radiological grounds but is much easier histologically if the surgeon provides a generous specimen and the pathologist is alert to the morphological features on routine examination with H & E and more specifically to judicious selection of MAbs using immunohistochemical techniques.
Earlier reports of CNS rhabdoid tumors have emphasized the unique rhabdoid cells comprising the neoplasms and have paid scant attention to other cellular elements. Although it is true that some of the ATT/RhTs are composed solely of rhabdoid cells (seven (13%) of 52 in our group) it is curious that the PNET, epithelial, or mesenchymal component present in so many of these 52 tumors has escaped the notice of experienced pathologists. A photomicrograph (Fig. 2) in the case report by Weeks, et al., 49 documents a field resembling a PNET but the authors do not call it such. Velasco, et al., 47 described fusiform cells in the CNS rhabdoid tumor that they observed and Hanna, et al., 21 specify histological subtypes similar to those described in renal rhabdoid tumors by Weeks, et al.; 48 in particular "epithelioid, spindled and sclerosing."
Parham and colleagues 36 provide the most detailed description of histological variation within primary CNS rhabdoid tumors in Table 4 of the paper in which they analyze 11 such tumors.
The combination of PNET, rhabdoid, epithelial, and mesenchymal features that characterize this group of tumors is unique. Such disparate elements suggest that the tumor is a special type of teratoma. However, the tumors do not resemble classic teratomas in any other way, including location, and gross or microscopic appearance. In addition there is a consistent lack of positivity for any of the standard immunohistochemical markers for germcell tumors. In this connection, Nakagawa, et al., 33 called attention to immunohistochemical differences between intracranial germinomas and their gonadal equivalents. Three of 11 intracranial tumors that they called germinomas stained positively for EMA, cytokeratin, and vimentin, whereas essentially none of the gonadal tumors exhibited such features. These three patients are of particular interest because one was a 22-month-old girl with a pineal tumor, one a 3-month-old boy with a posterior fossa neoplasm (specific site is not noted), and one was a 13 yearold-girl with a cerebellar germinoma. Photomicrographs in Fig. 1A to C of their paper look suspiciously similar to rhabdoid tumors.
When the problem of naming this unique tumor presented itself, it seemed appropriate to call attention to the unusual combination of mixed cellular elements similar to but not typical of teratomas and the rhabdoid cells; hence, the name atypical teratoid/rhabdoid tumor was created.
Comparison of the histological patterns of the CNS ATT/RhT with those described in the kidney reveal a more restricted range of expression among the CNS lesions. In their review of 111 malignant rhabdoid tumors of the kidney, Weeks, et al., 48 described six major patterns and 18 subtypes within five of those six patterns. In contrast, the CNS counterpart to the renal rhabdoid tumor is much simpler; it is composed entirely of rhabdoid cells or is combined with fields indistinguishable from PNET (in 70%) and/or with neoplastic mesenchymal and/or epithelial tissue. In only one of the 52 tumors was there evidence of chondroid transformation.
It should also be emphasized that although there is a subtype of PNET-MB designated "desmoplastic," it bears no resemblance to the fields of neoplastic mesenchyme found in the ATT/RhT, and classic PNETS do not contain an epithelial component similar to that found in this unique tumor.
A careful search of the entire specimen for variations in pattern and cell type, along with application of the restricted group of antibodies using the immunoperoxidase technique, is most helpful for diagnosis. The three antibodies of greatest value are EMA, vimentin, and smooth-muscle actin in combination. Positivity for this triad is not found in typical PNETs; in fact, EMA is essentially never positive in primitive neuroectodermal cells. At the same time, although identification of GFAP and NFP is not surprising in the PNET areas of the ATT/RhTs, the presence of these antigens in the rhabdoid cells is intriguing. When sought, GFAP and NFP have also been identified in a small number of non-CNS rhabdoid tumors. 21, 34, 45, 49 Moreover, Ota, et al., 35 established cell lines from two peripheral malignant rhabdoid tumors, one renal and the other retroperitoneal. Cultured cells from the renal rhabdoid tumor demonstrated neural, epithelial, and mesenchymal markers (and a 22q11.2 chromosomal abnormality) while the cells from the extrarenal rhabdoid tumor exhibited morphological changes of neuroblastic differentiation with numerous neuritic processes.
All of these observations inevitably lead to questions about the nature of the rhabdoid cell. A variety of studies have already found that it is of histiocytic, 19 mesenchymal, 6 ,16 neuroectomesenchymal, 35 or meningeal lineage. 10 Its resemblance to the germ cell (of germinoma), at least at the light-microscopic level, leads to further speculation that the rhabdoid cell is a transformed highly malignant germ cell with a capacity for multipotential differentiation. We have insufficient knowledge at this point to resolve this question. Our studies indicate that classic CNS PNETs can be separated from CNS ATT/RhTs on cytogenetic grounds. The CNS ATT/RhTs (and peripheral malignant rhabdoid tumors) have demonstrated an association with deletions of chromosome 22. Indeed, our analyses of 15 of these tumors has shown monosomy or deletion of chromosome 22 in nine of the 15 tumors. Douglass, et al., 13 found a monosomy 22 and deletion of part of the remaining 22 in one CNS rhabdoid tumor, whereas Karnes, et al., 26 found a variety of structural changes in another CNS rhabdoid tumor that did not involve chromosome 22. A CNS PNET in a patient with a renal rhabdoid tumor was also shown to have a monosomy 22. 15 Although a limited number of PNET-MBs have been reported to have a monosomy of chromosome 22, the most common abnormality in CNS PNETs is an i(17q) present in 50% of cases. 5 It is conceivable that those CNS PNETs that have been reported to have a monosomy 22 are actually misdiagnosed ATT/RhTs. 46 Deletion of sequences from chromosome 22q11 in ATT/RhTs implicates the presence of a tumor-suppressor gene involved in the development or progression of these tumors. Strategies designed to narrow the region of loss on chromosome 22 have implicated a region on 22 in the proximity of the B-cell reactivity locus that should contain a rhabdoid tumor gene. 4 The identification of this gene should provide greater understanding of the molecular genetic events that lead to tumorigenesis in children with malignant brain tumors.
